A Guide to Sublingual Immunotherapy in Japan

Area of Science:

• Allergy and Immunology
• Pharmacology
• Otolaryngology

Background:

• Allergen immunotherapy (AIT) offers sustained remission for Type I allergies.
• Sublingual immunotherapy (SLIT) is the sole AIT option in Japan for Japanese cedar pollinosis (JCP) and house dust mite (HDM) allergies.
• SLIT is recognized for its efficacy and safety in managing allergic rhinitis.

Purpose of the Study:

• To evaluate the efficacy and safety of SLIT tablets for JCP and HDM allergies in Japan.
• To assess the potential for concomitant administration of JCP and HDM SLIT tablets.
• To examine the cross-efficacy of JCP SLIT against Japanese cypress pollinosis.

Main Methods:

• Clinical studies involving SLIT tablets for JCP and HDM allergies.
• Japanese multicenter studies assessing concomitant administration safety.
• Analysis of treatment duration, adherence rates, and clinical benefits.

Main Results:

• SLIT tablets reduced symptom scores by approximately 30% with a high safety profile.
• Most adverse events were mild, local irritations; serious events were rare.
• Concomitant administration of JCP and HDM SLIT tablets was confirmed as safe.
• JCP SLIT demonstrated cross-efficacy for Japanese cypress pollinosis.
• A high adherence rate of approximately 80% was observed.

Conclusions:

• SLIT tablets are effective and safe for managing allergic rhinitis caused by JCP and HDM in Japan.
• The non-invasive nature and sustained efficacy of SLIT contribute to its central role in allergic rhinitis management.
• Proper patient selection and education are crucial for optimizing SLIT adherence and outcomes.